Journal of Cancer Immunology & Therapy

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (202) 780-3397

Perspective - Journal of Cancer Immunology & Therapy (2023) Volume 6, Issue 4

Preference of Angiogenesis: A New Frontier in Cancer Therapy

Sin Uho *

Department of Medicine

*Corresponding Author:
Sin Uho
Department of Medicine
Albert Einstein College of Medicine
New York
E-mail: sin.uhou@einsteinmed.edu

Received:29-Jul-2023,Manuscript No. AAJCIT-23-109865; Editor assigned: 03-Aug-2023, PreQC No. AAJCIT-23-109865 (PQ); Reviewed:17-Aug -2023, QC No. AAJCIT-23-109865; Revised:22-Aug -2023, Manuscript No. AAJCIT-23-109865 (R); Published:30-Aug -2023, DOI: 10.35841/aajcit- 6.4.164

Citation: Uho S. Preference of angiogenesis: A new frontier in cancer therapy. J Cancer Immunol Ther. 2023;6(4):164

Visit for more related articles at Journal of Cancer Immunology & Therapy

Abstract

  

Introduction

Cancer remains one of the most formidable challenges in modern medicine, affecting millions of lives globally each year. Conventional treatment approaches, such as surgery, chemotherapy, and radiation therapy, have made significant strides in combating various cancer types. However, their limitations and adverse effects have driven the search for innovative and targeted therapies. In recent years, the emerging fields of cancer immunology and angiogenesis have opened new vistas in the fight against cancer, offering promising avenues for more effective and personalized treatments. Cancer immunology is a branch of immunology dedicated to understanding the complex interplay between the immune system and cancer cells. The immune system's ability to recognize and eliminate abnormal cells is a fundamental defense mechanism in the body. However, cancer cells often evade immune surveillance through various mechanisms, allowing them to proliferate uncontrollably. Researchers have been exploring ways to harness the immune system's power to specifically target and destroy cancer cells, giving rise to immunotherapies [1].

Immunotherapies work by either enhancing the natural immune response against cancer or by artificially equipping the immune system to recognize and attack cancer cells. Among the most revolutionary breakthroughs in this field is immune checkpoint therapy, which involves blocking inhibitory signals that prevent immune cells from attacking cancer cells. This has led to remarkable responses in certain cancer types, demonstrating the potential of cancer immunotherapy as a transformative treatment option [2].

Angiogenesis, the process of forming new blood vessels, plays a crucial role in various physiological and pathological processes, including cancer growth and metastasis. Solid tumors require a blood supply to sustain their rapid growth, and angiogenesis provides the necessary nutrients and oxygen. Tumor cells can stimulate the formation of new blood vessels through the secretion of pro-angiogenic factors, such as vascular endothelial growth factor (VEGF).Given the significance of angiogenesis in tumor growth and progression, researchers have targeted this process as a potential avenue for cancer therapy. Anti-angiogenic therapies aim to disrupt the formation of new blood vessels in tumors, thereby starving the cancer cells of their vital nutrients and oxygen supply. These therapies can be used alone or in combination with other treatments, such as chemotherapy or immunotherapy, to enhance their efficacy and reduce the risk of treatment resistance [3].

Recent research has highlighted the interconnectedness between cancer immunology and angiogenesis. Immunotherapies have shown the potential to modulate the tumor microenvironment and impact the process of angiogenesis. Additionally, anti-angiogenic therapies have demonstrated the ability to influence immune responses within tumors, indicating a bidirectional crosstalk between these two fields. Combining immunotherapies with anti-angiogenic agents has emerged as a compelling strategy to achieve synergistic effects in cancer treatment. These combination therapies have shown promising results in preclinical and clinical studies, fostering the hope of a more comprehensive and effective approach to combat cancer. Moreover, the integration of precision medicine, which takes into account the genetic makeup of both the tumor and the patient's immune system, has opened doors for personalized cancer treatments with improved outcomes [4].

In recent years, significant strides have been made in the field of Cancer Immunology & Therapy, unveiling promising new approaches for combating this devastating disease. Among these breakthroughs, the study of angiogenesis has emerged as a crucial avenue for therapeutic interventions. Angiogenesis, the process of new blood vessel formation, plays a pivotal role in tumor growth and metastasis, making it an attractive target for innovative treatment strategies. Immunotherapy, a revolutionary approach in cancer treatment, has transformed the landscape of cancer care. Unlike traditional treatments like chemotherapy and radiation, which directly attack cancer cells, immunotherapy harnesses the body's immune system to recognize and eliminate cancer cells. Immune checkpoint inhibitors are a prominent example of such therapies, where specific checkpoints on immune cells are targeted to unleash their potential in fighting cancer. Although highly effective in some cases, immunotherapy's success is limited in certain cancers, calling for the exploration of additional avenues to enhance treatment outcomes [5].

 

References

  1. Giraldo NA, Becht E, Remark R, et al The immune contexture of primary and metastatic human tumours Curr Opin Immunol. 2014;27:8-15.

    2. Indexed at, Google Scholar, Cross Ref

  2. Snyder A, Chan TA.Immunogenic peptide discovery in cancer genomes.. Curr Opin Genet Dev. 2015;30:7-16.

    3. Indexed at, Google Scholar,Cross Ref

  3. Mlecnik B, Tosolini M, Kirilovsky A, et al . Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol. 2011;29(6):610-8.

    4. Indexed at, Google Scholar, Cross Ref

  4. Britten CM, Janetzki S, Van der Burg SH, et al.Minimal information about T cell assays: The process of reaching the community of T cell immunologists in cancer and beyond. Cancer Immunol Immunother. 2011;60:15-22.

     

  5. Groth C, Hu X, Weber R, et al. Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression Br J Cancer. 2019;120(1):16-25.

    6. Indexed at, Google Scholar, Cross Ref

Get the App